Highest-materiality recent filing
MapLight raises $150M PIPE, Q2 net loss $60.2M; ZEPHYR Phase 2 met primary endpoint
$150M PIPE: 9,197,887 shares at $11.38/share plus pre-funded warrants for 3,983,168 shares; closes Aug 14, 2026
MapLight reports positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia
Primary endpoint met: 210/3 mg BID dose showed statistically significant PANSS total score reduction vs placebo (effect size 0.37, p=0.015, LS mean diff -4.5).
MapLight Therapeutics elects three directors, ratifies RSM US LLP as auditor
Martin Babler, Troy Cox, George Pavlov elected as directors with 89.8%, 99.9%, 97.8% of votes cast.
MapLight's ML-004 Phase 2 misses primary endpoint in autism; shows signal in adolescent irritability
Primary endpoint (ABI-Social Communication) not met in Phase 2 IRIS trial of ML-004 in ASD.
MapLight Therapeutics fires CFO Vishwas Setia for HR violation; interim CFO named
Vishwas Setia separated as CFO effective June 18, 2026, due to human resources violation; no severance paid.
MapLight Therapeutics Q1 net loss $60.7M; completes enrollment in two Phase 2 trials
Net loss of $60.7M in Q1 2026 vs $22.3M YoY; R&D expenses $53.7M, G&A $10.8M.
Two MapLight directors not standing for reelection; Babler and Cox nominated
Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D. will not stand for reelection at the June 23, 2026 Annual Meeting.
MapLight Q4 net loss $79.5M; cash $453M; Phase 2 readouts expected Q3 2026
Net loss of $79.5M in Q4 2025 vs $21.2M year ago; FY2025 loss $161.2M vs $77.6M.
MapLight reports $450M cash; Phase 2 ZEPHYR & IRIS topline results now expected Q3 2026
Preliminary cash and equivalents ~$450M as of Dec 31, 2025.
MapLight reports Q3 net loss $29.4M; cash runway through 2027; Phase 2 readouts in 2026-2027
Net loss $29.4M vs $19.0M in Q3 2024; R&D spend $27.1M (up 61% YoY) on clinical trial costs.
MapLight Therapeutics prices IPO at $17/sh, raises $296.3M including concurrent private placement
IPO of 14.75M shares at $17.00; underwriters fully exercise option for 2.2125M additional shares.
Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the “Company”), effective immediately, following a review of a human resources violation.
the board of directors of the Company appointed Jonathan Gillis, the Company’s Chief Administrative and Accounting Officer, as the Company’s interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
Max materiality 0.85 · Median 0.75 · Most common event other_material